XML 84 R72.htm IDEA: XBRL DOCUMENT
v3.22.0.1

Collaborations and Other Arrangements (Details) € / shares in Units, € in Millions, shares in Millions |  |  |  |  |  |  |  | 1 Months Ended | 3 Months Ended | 12 Months Ended |  |  |  |  |  |  |  |  |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Dec. 21, 2021 USD ($) | Mar. 13, 2021 USD ($) | Aug. 25, 2020 USD ($) | Aug. 17, 2020 USD ($) program | Jul. 13, 2020 USD ($) shares | May 29, 2020 USD ($) shares | May 27, 2020 | Jan. 31, 2021 USD ($) | Jan. 31, 2021 EUR (€) | Oct. 31, 2020 USD ($) | Aug. 31, 2019 USD ($) shares | Dec. 31, 2018 USD ($) | Mar. 31, 2021 USD ($) shares | Dec. 31, 2021 USD ($) shares | Dec. 31, 2020 USD ($) | Dec. 31, 2019 USD ($) shares | Dec. 31, 2014 | Dec. 31, 2021 EUR (€) shares | Nov. 18, 2021 program | Apr. 30, 2021 USD ($) | Apr. 30, 2021 EUR (€) | Feb. 08, 2021 | Dec. 15, 2020 EUR (€) | Jul. 17, 2020 | Jun. 19, 2020 | Aug. 31, 2019 € / shares | Jul. 31, 2018 USD ($) | Jan. 19, 2016 € / shares shares
Collaborative Arrangements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquired in-process research and development expenses |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 177,000,000 | $ 5,856,000,000 | $ 4,251,000,000 |  |  |  |  |  |  |  |  |  |  |  |
Unrealized loss on investment of equity securities |  |  |  |  |  |  |  |  |  |  |  |  |  | 610,000,000 | 1,700,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Unrealized gain on investment of equity securities |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,200,000,000 |  |  |  |  |  |  |  |  |  |  |  |
Prepaid and other current assets |  |  |  |  |  |  |  |  |  |  |  |  |  | 2,141,000,000 | 2,013,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Other long-term assets |  |  |  |  |  |  |  |  |  |  |  |  |  | 4,963,000,000 | 5,708,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Cost of goods sold |  |  |  |  |  |  |  |  |  |  |  |  |  | 6,601,000,000 | 4,572,000,000 | 4,675,000,000 |  |  |  |  |  |  |  |  |  |  |  |
Merck Sharp & Dohme Corp |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percent of global and development and commercialization costs |  | 60.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenues recognized |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Option period to license certain inhibitors |  | 5 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Merck Sharp & Dohme Corp | Oral Formulation Product |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Net product sales threshold |  | $ 2,000,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percent of global product revenues |  | 65.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Merck Sharp & Dohme Corp | Injectable Formulation Product |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Net product sales threshold |  | $ 3,500,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Merck Sharp & Dohme Corp | Merck |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percent of global and development and commercialization costs |  | 40.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Arcus stock purchase agreement | Arcus |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Ownership percentage by noncontrolling owners |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 19.50% |  |  |  |  |  |
Janssen pharmaceuticals |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Purchase price of goods less specified amount, maximum percentage |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 30.00% |  |  |  |  |  |  |  |  |  |  |
Cost of goods sold |  |  |  |  |  |  |  |  |  |  |  |  |  | 530,000,000 | 570,000,000 | 574,000,000 |  |  |  |  |  |  |  |  |  |  |  |
Period subject to termination |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 10 years |  |  |  |  |  |  |  |  |  |  |
Jounce license and stock purchase agreement | Jounce |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Ownership percentage by noncontrolling owners |  |  |  |  |  |  |  |  |  | 14.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Japan tobacco |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Royalty expense |  |  |  |  |  |  |  |  |  |  |  |  |  | 250,000,000 | 291,000,000 | 358,000,000 |  |  |  |  |  |  |  |  |  |  |  |
Cash paid |  |  |  |  |  |  |  |  |  |  |  | $ 559,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-lived intangible assets acquired |  |  |  |  |  |  |  |  |  |  |  | $ 550,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Amortization useful life |  |  |  |  |  |  |  |  |  |  |  | 9 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Gadeta collaboration arrangement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Noncontrolling interest in variable interest entity |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 82,000,000 |  |  |  |  |  |  |  |  |  |  | $ 82,000,000 |
Other collaboration arrangements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cash payments made related to equity investments |  |  |  |  |  |  |  |  |  |  |  |  |  | 147,000,000 | 72,000,000 | 118,000,000 |  |  |  |  |  |  |  |  |  |  |  |
Upfront collaboration expenses |  |  |  |  |  |  |  |  |  |  |  |  |  | 177,000,000 | 129,000,000 | 331,000,000 |  |  |  |  |  |  |  |  |  |  |  |
Arcus |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payments to acquire shares |  |  |  |  |  | $ 61,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Shares of common stock acquired (in shares) | shares |  |  |  |  |  | 2.2 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Arcus | Arcus collaboration agreement and stock purchase agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payments to acquire in process research and development |  |  |  |  | $ 175,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Additional shares acquired (in shares) | shares |  |  |  |  | 6.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payments to acquire shares |  |  |  |  | $ 200,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total upfront payments made |  |  |  |  | 391,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity investment |  |  |  |  | 135,000,000 |  |  |  |  |  |  |  |  | 559,000,000 | 212,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Acquired in-process research and development expenses |  |  |  |  | 256,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Issuance discount (premium) |  |  |  |  | (65,000,000) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Direct transactional costs |  |  |  |  | 16,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Opt-in term |  |  |  |  |  |  | 10 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of clinical stage programs with exercise options | program |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 3 |  |  |  |  |  |  |  |  |
Collaboration opt-in payments | $ 725,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development expenses |  |  |  |  |  |  |  |  |  |  |  |  |  | 625,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Unrealized gain on investment of equity securities |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 127,000,000 | 80,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Arcus | Arcus collaboration agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Additional option fee on fourth, sixth, and eighth anniversaries |  |  |  |  | $ 100,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Arcus | Arcus stock purchase agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payments to acquire shares |  |  |  |  |  |  |  |  |  |  |  |  | $ 220,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Purchase period |  |  |  |  | 5 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum percentage of outstanding stock allowed to be purchased |  |  |  |  | 35.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Restriction period |  |  |  |  | 3 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Additional shares acquired (in shares) | shares |  |  |  |  |  |  |  |  |  |  |  |  | 5.7 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of shares (in shares) | shares |  |  |  |  |  |  |  |  |  |  |  |  |  | 13.8 |  |  |  | 13.8 |  |  |  |  |  |  |  |  |  |
Pionyr |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Ownership percentage |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 49.90% |  |  |
Pionyr | Pionyr merger and option agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquired in-process research and development expenses |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 215,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Equity investments balance |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 0 | 0 |  |  |  |  |  |  |  |  |  |  |  |  |
Payments to acquire equity method investments |  |  |  |  | $ 269,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Estimated fair value |  |  |  |  | 70,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Option exercise fee |  |  |  |  | 315,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum potential future milestone payments |  |  |  |  | 1,200,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Pionyr | Research and development service agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquired in-process research and development expenses |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 80,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development future maximum payments |  |  |  |  | $ 115,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cash payments made for research and development milestones |  |  |  |  |  |  |  |  |  |  |  |  | $ 70,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Tizona |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Ownership percentage |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 49.90% |  |  |  |
Tizona | Tizona merger and option agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquired in-process research and development expenses |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 272,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Equity investments balance |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 |  |  |  |  |  |  |  |  |  |  |  |  |
Payments to acquire equity method investments |  |  | $ 302,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Estimated fair value |  |  | 41,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Option exercise fee |  |  | 100,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Tizona | Tizona merger and option agreements | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Option fee and potential future milestone payments |  |  | $ 1,200,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Tizona | Development agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquired in-process research and development expenses |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 115,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Tango | Tango collaboration and stock purchase agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payments to acquire in process research and development |  |  |  | $ 125,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payments to acquire shares |  |  |  | 13,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquired in-process research and development expenses |  |  |  | $ 125,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration term |  |  |  | 7 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cash payments made related to equity investments |  |  |  | $ 20,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of programs | program |  |  |  | 15 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Tango | Tango collaboration and stock purchase agreement | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Opt-in, extension and milestone payments |  |  |  | $ 410,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Jounce | Jounce license and stock purchase agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total upfront payments made |  |  |  |  |  |  |  |  |  | $ 120,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquired in-process research and development expenses |  |  |  |  |  |  |  |  |  |  |  |  |  | 64,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cash payments made related to equity investments |  |  |  |  |  |  |  |  |  | $ 56,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Future potential clinical, regulatory and commercial milestone payments |  |  |  |  |  |  |  |  |  |  |  |  |  | 660,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Galapagos | Filgotinib agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Shares of common stock acquired (in shares) | shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 6.8
Share price (in dollars per share) | € / shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | € 58
Galapagos | Amended 2019 agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payment of tiered royalties, low-end percentage |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 8.00% |  |  |  |  |
Payment of tiered royalties, high-end percentage |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 15.00% |  |  |  |  |
Potential payment for adjustments of budgeted development costs |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 190,000,000 |  |  |  |  |  |  | € 160 |  |  |  |  |
Payment for adjustments of budgeted development costs |  |  |  |  |  |  |  | $ 43,000,000 | € 35 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Additional payment for adjustments of budgeted development costs in 2021 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 88,000,000 | € 75 |  |  |  |  |  |  |
Payment for adjustments of budgeted development costs in 2022 |  |  |  |  |  |  |  |  |  |  |  |  |  | 60,000,000 |  |  |  | € 50 |  |  |  |  |  |  |  |  |  |
Galapagos | Galapagos subscription agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Additional shares acquired (in shares) | shares |  |  |  |  |  |  |  |  |  |  | 2.6 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquired in-process research and development expenses |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 3,920,000,000 |  |  |  |  |  |  |  |  |  |  |  |
Shares of common stock acquired (in shares) | shares |  |  |  |  |  |  |  |  |  |  | 6.8 |  |  |  |  | 16.7 |  |  |  |  |  |  |  |  |  |  |  |
Equity investments balance |  |  |  |  |  |  |  |  |  |  | $ 1,130,000,000 |  |  | 931,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Unrealized loss on investment of equity securities |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 717,000,000 | 1,800,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Unrealized gain on investment of equity securities |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,200,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Ownership percentage |  |  |  |  |  |  |  |  |  |  | 25.80% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Share price (in dollars per share) | € / shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | € 140.59 |  |
Estimated fair value |  |  |  |  |  |  |  |  |  |  | $ 586,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payment for license and option rights |  |  |  |  |  |  |  |  |  |  | 5,050,000,000.00 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Issuance discount |  |  |  |  |  |  |  |  |  |  | $ 63,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum ownership percentage |  |  |  |  |  |  |  |  |  |  | 29.90% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Standstill restricting term |  |  |  |  |  |  |  |  |  |  | 10 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Minimum ownership percentage |  |  |  |  |  |  |  |  |  |  | 20.10% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Prepaid and other current assets |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 351,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Other long-term assets |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 1,300,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Galapagos | Galapagos collaboration agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payment of tiered royalties, low-end percentage |  |  |  |  |  |  |  |  |  |  | 20.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payment of tiered royalties, high-end percentage |  |  |  |  |  |  |  |  |  |  | 24.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential option exercise fee |  |  |  |  |  |  |  |  |  |  | $ 150,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

X
- Definition Adjustments of Budgeted Development Costs, Payments + References No definition available. + Details
Name: | gild_AdjustmentsOfBudgetedDevelopmentCostsPayments
Namespace Prefix: | gild_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Adjustments of Budgeted Development Costs, Payments, Due Next Twelve Months + References No definition available. + Details
Name: | gild_AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueNextTwelveMonths
Namespace Prefix: | gild_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Cash Payments Made Related To Equity Investments + References No definition available. + Details
Name: | gild_CashPaymentsMadeRelatedToEquityInvestments
Namespace Prefix: | gild_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Collaboration Arrangement, License Oral Integrase Inhibitors, Option Period + References No definition available. + Details
Name: | gild_CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod
Namespace Prefix: | gild_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaboration Arrangement, Net Product Sales Threshold + References No definition available. + Details
Name: | gild_CollaborationArrangementNetProductSalesThreshold
Namespace Prefix: | gild_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Collaboration Arrangement, Percent Of Global Development And Commercialization Costs + References No definition available. + Details
Name: | gild_CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts
Namespace Prefix: | gild_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaboration Arrangement, Percent Of Global Product Revenues + References No definition available. + Details
Name: | gild_CollaborationArrangementPercentOfGlobalProductRevenues
Namespace Prefix: | gild_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaborative Agreement, Opt-In Term + References No definition available. + Details
Name: | gild_CollaborativeAgreementOptInTerm
Namespace Prefix: | gild_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaborative Agreement, Product Market Period Subject To Termination + References No definition available. + Details
Name: | gild_CollaborativeAgreementProductMarketPeriodSubjectToTermination
Namespace Prefix: | gild_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaborative Arrangement, Term + References No definition available. + Details
Name: | gild_CollaborativeArrangementTerm
Namespace Prefix: | gild_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Equity Method Investment, Option Exercise Fee + References No definition available. + Details
Name: | gild_EquityMethodInvestmentOptionExerciseFee
Namespace Prefix: | gild_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Equity Method Investment, Option Fee And Potential Future Milestone Payments + References No definition available. + Details
Name: | gild_EquityMethodInvestmentOptionFeeAndPotentialFutureMilestonePayments
Namespace Prefix: | gild_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Equity Securities, FV-NI, Additional Option Fee on Fourth, Sixth, and Eighth Anniversaries + References No definition available. + Details
Name: | gild_EquitySecuritiesFVNIAdditionalOptionFeeOnFourthSixthAndEighthAnniversaries
Namespace Prefix: | gild_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Equity Securities, FV-NI, Maximum Percentage Of Outstanding Stock Allowed To Be Purchased + References No definition available. + Details
Name: | gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased
Namespace Prefix: | gild_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Equity Securities, FV-NI, Option Opt-in, Extension and Milestone Payments + References No definition available. + Details
Name: | gild_EquitySecuritiesFVNIOptionOptInExtensionAndMilestonePayments
Namespace Prefix: | gild_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Equity Securities, FV-NI, Purchase Period + References No definition available. + Details
Name: | gild_EquitySecuritiesFVNIPurchasePeriod
Namespace Prefix: | gild_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Equity Securities, FV-NI, Restriction Period + References No definition available. + Details
Name: | gild_EquitySecuritiesFVNIRestrictionPeriod
Namespace Prefix: | gild_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Equity Securities, FV-NI, Shares + References No definition available. + Details
Name: | gild_EquitySecuritiesFVNIShares
Namespace Prefix: | gild_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Equity Securities, FV-NI, Shares Acquired + References No definition available. + Details
Name: | gild_EquitySecuritiesFVNISharesAcquired
Namespace Prefix: | gild_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Initial consideration for acquisition of rights to market and distribute certain products in Japan + References No definition available. + Details
Name: | gild_InitialConsiderationforAcquisitionofRightstoMarketandDistributeCertainProductsinJapan
Namespace Prefix: | gild_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Investment Owned, Balance, Additional Shares + References No definition available. + Details
Name: | gild_InvestmentOwnedBalanceAdditionalShares
Namespace Prefix: | gild_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Issuance Discount (Premium) + References No definition available. + Details
Name: | gild_IssuanceDiscountPremium
Namespace Prefix: | gild_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Issuance discount + References No definition available. + Details
Name: | gild_Issuancediscount
Namespace Prefix: | gild_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Maximum Ownership Percentage in Galapagos Based on the Terms of the Subscription Agreement + References No definition available. + Details
Name: | gild_MaximumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement
Namespace Prefix: | gild_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Minimum Ownership Percentage in Galapagos Based on the Terms of the Subscription Agreement + References No definition available. + Details
Name: | gild_MinimumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement
Namespace Prefix: | gild_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number Of Clinical Stage Programs With Exercised Options + References No definition available. + Details
Name: | gild_NumberOfClinicalStageProgramsWithExercisedOptions
Namespace Prefix: | gild_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of Programs + References No definition available. + Details
Name: | gild_NumberOfPrograms
Namespace Prefix: | gild_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Payment for Adjustments of Budgeted Development Costs + References No definition available. + Details
Name: | gild_PaymentForAdjustmentsOfBudgetedDevelopmentCosts
Namespace Prefix: | gild_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition payment for license, option rights and equity investments upon closing of collaboration agreement + References No definition available. + Details
Name: | gild_PaymentforLicenseOptionRightsandEquityInvestmentsUponClosing
Namespace Prefix: | gild_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Payments for Direct Transactional Expense + References No definition available. + Details
Name: | gild_PaymentsForDirectTransactionalExpense
Namespace Prefix: | gild_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Payments for Research and Development Milestones + References No definition available. + Details
Name: | gild_PaymentsForResearchAndDevelopmentMilestones
Namespace Prefix: | gild_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Payments To Opt-In The Collaborative Agreement + References No definition available. + Details
Name: | gild_PaymentsToOptInTheCollaborativeAgreement
Namespace Prefix: | gild_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Potential Clinical, Regulatory and Commercial Milestone Payments, Maximum + References No definition available. + Details
Name: | gild_PotentialClinicalRegulatoryAndCommercialMilestonePaymentsMaximum
Namespace Prefix: | gild_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Potential Future Milestone Payments, Maximum + References No definition available. + Details
Name: | gild_PotentialFutureMilestonePaymentsMaximum
Namespace Prefix: | gild_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Potential Option Exercise Fee Per Program + References No definition available. + Details
Name: | gild_PotentialOptionExerciseFeePerProgram
Namespace Prefix: | gild_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Potential Payment for Adjustments of Budgeted Development Costs + References No definition available. + Details
Name: | gild_PotentialPaymentForAdjustmentsOfBudgetedDevelopmentCosts
Namespace Prefix: | gild_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Potential Sales Based Tiered Royalties High-end, Percentage + References No definition available. + Details
Name: | gild_PotentialSalesBasedTieredRoyaltiesHighEndPercentage
Namespace Prefix: | gild_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Potential Sales Based Tiered Royalty, Low-end, Percentage + References No definition available. + Details
Name: | gild_PotentialSalesBasedTieredRoyaltyLowEndPercentage
Namespace Prefix: | gild_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Purchase Price of Goods Less Specified Amount, Maximum Percentage + References No definition available. + Details
Name: | gild_PurchasePriceofGoodsLessSpecifiedAmountMaximumPercentage
Namespace Prefix: | gild_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Research and Development Future Maximum Payments + References No definition available. + Details
Name: | gild_ResearchAndDevelopmentFutureMaximumPayments
Namespace Prefix: | gild_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Standstill Restricting Term + References No definition available. + Details
Name: | gild_StandstillRestrictingTerm
Namespace Prefix: | gild_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Total Upfront Payments Made + References No definition available. + Details
Name: | gild_TotalUpfrontPaymentsMade
Namespace Prefix: | gild_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Up-front Collaboration and Licensing Expenses Related to Other Collaboration Arrangements That Are Not Individually Significant + References No definition available. + Details
Name: | gild_UpfrontCollaborationandLicensingExpensesRelatedtoOtherCollaborationArrangementsThatAreNotIndividuallySignificant
Namespace Prefix: | gild_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045 + Details
Name: | us-gaap_ContractWithCustomerLiabilityRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.2(a),(d)) -URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227 + Details
Name: | us-gaap_CostOfGoodsAndServicesSold
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571 + Details
Name: | us-gaap_EquityMethodInvestmentOwnershipPercentage
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.12) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_EquityMethodInvestments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Fair value portion of investments accounted under the equity method. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 25 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=125513658&loc=d3e32014-111567 + Details
Name: | us-gaap_EquityMethodInvestmentsFairValueDisclosure
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 45 -Paragraph 1A -URI http://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740 + Details
Name: | us-gaap_EquitySecuritiesFvNi
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of unrealized gain on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 321 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=123583765&loc=SL75117546-209714 + Details
Name: | us-gaap_EquitySecuritiesFvNiUnrealizedGain
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 321 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=123583765&loc=SL75117546-209714 + Details
Name: | us-gaap_EquitySecuritiesFvNiUnrealizedLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References No definition available. + Details
Name: | us-gaap_FiniteLivedIntangibleAssetUsefulLife
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275 + Details
Name: | us-gaap_FinitelivedIntangibleAssetsAcquired1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Balance held at close of period in number of shares. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 946 -SubTopic 210 -Section 50 -Paragraph 6 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=99383244&loc=d3e12121-115841 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 946 -SubTopic 320 -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column B)) -URI http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010 + Details
Name: | us-gaap_InvestmentOwnedBalanceShares
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity. + References No definition available. + Details
Name: | us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Portion of equity (net assets) in a variable interest entity (VIE) not attributable, directly or indirectly, to the parent entity. That is, this is the portion of equity in a VIE that is attributable to the noncontrolling interest (previously referred to as minority interest). + References No definition available. + Details
Name: | us-gaap_NoncontrollingInterestInVariableInterestEntity
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of noncurrent assets classified as other. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.17) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_OtherAssetsNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585 + Details
Name: | us-gaap_PaymentsToAcquireEquityMethodInvestments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of cash outflow to acquire investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 321 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=123583714&loc=SL75117360-209713 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 19 -URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3444-108585 + Details
Name: | us-gaap_PaymentsToAcquireEquitySecuritiesFvNi
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585 + Details
Name: | us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(7)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(8)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_PrepaidExpenseAndOtherAssetsCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 912 -SubTopic 730 -Section 25 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition. + References No definition available. + Details
Name: | us-gaap_ResearchAndDevelopmentInProcess
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.3) -URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227 + Details
Name: | us-gaap_RoyaltyExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Price of a single share of a number of saleable stocks of a company. + References No definition available. + Details
Name: | us-gaap_SharePrice
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_VariableInterestEntityLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OralFormulationProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_InjectableFormulationProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=gild_MerckMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=gild_ArcusStockPurchaseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_OwnershipAxis=gild_ArcusBiosciencesIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=gild_JanssenPharmaceuticalsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=gild_LicenseRegistrationRightsAndStockPurchaseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_OwnershipAxis=gild_JounceTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=gild_AgreementWithJapanTobaccoIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=gild_GadetaBVCollaborationArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=gild_OtherCollaborationArrangementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_ArcusBiosciencesIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=gild_ArcusCollaborationAgreementAndStockPurchaseAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=gild_ArcusCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_PionyrImmunotherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=gild_PionyrMergerAndOptionAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=gild_ResearchAndDevelopmentServiceAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_TizonaTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=gild_TizonaMergerAndOptionAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=gild_DevelopmentAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_TangoTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=gild_AmendedAndRestatedResearchCollaborationAndLicenseAgreementAndStockPurchaseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_JounceTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_GalapagosMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=gild_FilgotinibLicenseAndCollaborationAgreementWithGalapagosMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=gild_AmendedFilgotinibLicenseAndCollaborationAgreementInDecember2020Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=gild_GalapagosSubscriptionAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=gild_GalapagosCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |